Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know
11:00am, Tuesday, 25'th Feb 2025
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
08:00am, Tuesday, 18'th Feb 2025
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Thursday, 13'th Feb 2025
ANN ARBOR, Mich., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 11, 2025, the Company granted ten new employees 58,300 restricted stock units (RSUs) under
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
07:00am, Wednesday, 18'th Dec 2024
– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt –
Esperion Announces $210 Million Convertible Debt Financing
06:00am, Friday, 13'th Dec 2024
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “A
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
08:00am, Thursday, 12'th Dec 2024
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commerciali
Will The Long Awaited Breakout For Esperion Therapeutics Hold?
07:43am, Sunday, 08'th Dec 2024
Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
11:10am, Tuesday, 03'rd Dec 2024
Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and cardiovascular risk. Shares rise.
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –
Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
02:08am, Wednesday, 13'th Nov 2024
I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:15pm, Friday, 08'th Nov 2024
ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs) under
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
12:00pm, Thursday, 07'th Nov 2024
ESPR reports a wider-than-expected loss for the third quarter of 2024. Revenues also lag estimates.
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
08:11am, Thursday, 07'th Nov 2024
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.37 per share a year ago.
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
06:00am, Thursday, 07'th Nov 2024
– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth –
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
08:00am, Monday, 04'th Nov 2024
ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesd
